CBP501 is entering Phase II trials for the treatment of non-small cell lung cancer. This chemotherapy drug is also undergoing Phase II trials for the treatment of malignant pleural mesothelioma. Pre-clinical information implies that CBP501 has the potential to cause cancer cell death by blocking the cancer cells from completing their cell cycle. The Phase I study showed that it may augment anti-cancer cytotoxicity when combined with other chemotherapy drugs.
CBP501 is being developed through collaboration between Japanese companies, CanBas Co., LTD, Takeda Pharmaceutical Company and Takeda’s wholly-owned subsidiary Millennium.
Information on the clinical trial for CBP501 can be found at the ClinicalTrials.gov site. For more information on available clinical trials, see our list or contact one of our mesothelioma family advocates.
